Summary of Background Research for Vasopressin in Renal Failure

**Conducted on February 2024**

# Table of Contents

**1. Title**

**2. Objective**

**3. A summary of findings from nonclinical in vitro or in vivo studies that have potential clinical significance**

*3.1 Summary*

*3.2 Background*

*3.3 Structure*

*3.4 Weight*

*3.5 Chemical Formula*

*3.6 Indications and usage*

*3.7 Associated Conditions*

*3.8 Associated Therapies*

*3.9 Mechanism of action*

*3.10 Metabolism*

*3.11 Route of elimination*

*3.12 Half life*

*3.13 Toxicity*

*3.14 Dosage and administration*

*3.15 Contraindications of the drug*

*3.16 Warnings and precautions*

*3.17 Clinical Pharmacology- Pharmacodynamics, Pharmacokinetics*

*3.18 Non-clinical toxicology*

*3.19 Clinical Studies*

*3.20 Storage and handling*

**4. A summary of relevant clinical research and any history of human use or exposure to the study intervention, including use in other countries, and clinical pharmacology studies**

*4.1 Results Overview from previous clinical trials*

*4.2 Trial Description: Brief Summary of study type/design*

*4.3 Drug trial snapshots*

*4.4 Participant Flow*

*4.5 Record History*

*4.6 Study record dates*

*4.7 Intervention and Treatment*

*4.8 Outcome Measures of previous clinical trials*

**5. Discussion of important literature and data that are relevant to the trial and that provide background for the trial**

*5.1 Summary of related research articles*

*5.2 Main outcomes and measures- of research articles*

*5.3 Demographic profile*

*5.4 Study Design for background*

**6. Applicable clinical, epidemiological, or public health background or context of the clinical trial**

*6.1 Importance of the research*

*6.2 Objective of the research*

*6.3 Use of the drug in specific populations*

**7. Importance of the clinical trial and any relevant treatment issues or controversies**

*7.1 Adverse events*

*7.2 Possible side effects*

*7.3 Drug interactions*

*7.4 Over dosage*

**2. Objective**

The objective of this document is to generate concise and informative summaries of previous clinical trials sourced from various data repositories. The automated summary will extract key information from diverse clinical trial datasets, condensing the findings into digestible formats for easy consumption by researchers, healthcare professionals, and decision-makers

**3. Findings from nonclinical in vitro or in vivo studies that have potential clinical significance**

**3.1 Summary**

Enter data here

**3.2 Background**

Enter data here

**3.3 Structure**

Enter data here

**3.4 Weight**

Enter data here

**3.5 Chemical Formula**

Enter data here

**3.6 Indications and Usage**

Enter data here

**3.7 Associated conditions**

Enter data here

**3.8 Associated therapies**

Enter data here

**3.9 Mechanism of Action**

Enter data here

**3.10 Metabolism**

Enter data here

**3.11 Route of elimination**

Enter data here

**3.12 Half life**

Enter data here

**3.13 Toxicity**

Enter data here

**3.14 Dosage and Administration**

Enter data here

**3.15 Contradictions**

Enter data here

**3.16 Warnings and precautions**

Enter data here

**3.17 Clinical Pharmacology**

Enter data here

**3.18 Non-clinical toxicology**

Enter data here

**3.19 Clinical Studies**

Enter data here

**3.20 Storage and handling**

Enter data here

**4 Summary of relevant clinical research and any history of human use or exposure to the study intervention, including use in other countries, and clinical pharmacology studies**

**4.1 Results Overview**

Conditions: Hypertension, End Stage Renal Disease

**4.2 Trial Description**

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Primary Purpose: Treatment

**4.3 Drug trial snapshot of related drugs**

TERLIVAZ is a vasopressin receptor agonist indicated for improving kidney function in adults diagnosed with hepatorenal syndrome (HRS) and experiencing rapid reduction in kidney function.

TERLIVAZ is administered via injection every six hours, with treatment duration extending up to 14 days.

The FDA approval of TERLIVAZ relied on findings from the CONFIRM clinical trial, which enrolled 199 patients diagnosed with HRS and experiencing rapid decline in kidney function. The trial was conducted across 60 sites spanning two countries: United States (55 sites) and Canada (5 sites). Both efficacy and safety assessments were conducted within the same trial.

The effectiveness of TERLIVAZ was evaluated through a double-blind study design. Participants diagnosed with HRS and encountering rapid kidney function decline were randomly assigned to receive either TERLIVAZ (199 participants) or a placebo (101 participants). The treatment regimen involved intravenous administration of either 0.85 mg of TERLIVAZ or a placebo every six hours for a maximum duration of 14 days. Dosing adjustments were made based on changes in kidney function.

**4.4 Participant flow**

|  |  |  |  |
| --- | --- | --- | --- |
| **Arm/Group Title** | **Very low dose** | **Low dose** | **Placebo** |
| Arm/Group Description | Very Low Dose: Active Comparator 0.15 mU per kg per minute | Low Dose: Active Comparator 0.30 mU per kg per minute | No Dose - Placebo Comparator |
| Overall Study | | | |
| Started | 4 | 4 | 4 |
| Completed | 3 | 3 | 4 |
| Not Completed | 1 | 1 | 0 |
| Reason not completed | | | |
| Physician Decision | 1 | 0 | 0 |
| Withdrawal by Subject | 0 | 1 | 0 |

**4.5 Record History**



**4.6 Study record dates**

First Submitted

2010-11-22

First Posted

2010-11-24

Results First Submitted

2011-04-04

Results First Posted

2011-04-28

Last Update Posted

2019-11-18

Last Verified

2019-10

**4.7 Intervention and Treatment**

Drug: Vasopressin - Very Low Dose

Drug: Vasopressin - Low Dose

Drug: Placebo Comparator

**4.8 Outcome and Measures**

**Primary (Current):** Change in Mean Interdialytic 44-hour Ambulatory Systolic Blood Pressure Over a 2 Week Follow-up Period [Time Frame: Baseline and Two Weeks]: This is designed to measure if the administration of intradialytic AVP will result in change in systolic blood pressure.

**Primary (Original):** Change in mean interdialytic 44-hour ambulatory blood pressure [Time Frame: (a) At baseline, before study visit 1, and (b) Two weeks later after visit 6 (the last pilot study treatment visit).]

**5.1 Summary of related research articles**

Acute renal failure (ARF) often occurs in critically ill patients, often with multisystem organ failure syndrome. While the mortality rate of ARF remains elevated, animal studies suggest that proactive measures and prompt intervention could potentially reduce both morbidity and mortality. This review outlines ARF criteria using indicators such as urine volume, laboratory metrics, and clinical symptoms.

Currently, norepinephrine is the recommended first-line vasopressor for treating septic shock. Nevertheless, some suggest considering early vasopressin administration as an alternative approach.

The influence of dietary protein intake on the progression of CHRONIC RENAL FAILURE may also involve VASOPRESSIN and the operation of the concentrating process. VASOPRESSIN receptors have been identified in glomeruli, and VASOPRESSIN can constrict mesangial cells as does angiotensin II. Acute VASOPRESSIN infusion increases the glomerular transcapillary hydraulic pressure difference, and chronic VASOPRESSIN infusion increases GFR.


**5.2 Main outcomes and measures of related research articles**

In adults experiencing septic shock, administering vasopressin early on instead of norepinephrine did not result in a significant improvement in the number of kidney failure-free days. While these results do not advocate for replacing norepinephrine with vasopressin as the initial treatment in such cases, it's worth noting that the confidence interval allowed for the possibility of a clinically significant benefit with vasopressin. Consequently, larger trials may be necessary to delve deeper into this potential benefit. The recent acknowledgment of acute kidney injury (AKI) as a potential precursor to chronic kidney disease and end-stage renal disease, along with the associated rise in mortality rates, has sparked interest in both the clinical epidemiology and mechanistic understanding of renal recovery following AKI episodes. Currently, there is no standardized definition for what constitutes recovery after AKI, and various factors need to be considered when formulating such a definition. The extent of renal recovery following an AKI incident can influence clinical decisions regarding the initiation of renal replacement therapy and holds significant implications for assessing biomarkers and identifying mechanistic targets for potential future clinical trials.

**5.3 Demographic profile**

The demographic of people involved in this study were:

* All 18 years and above
* In end Stage Renal Disease on Hemodialysis greater than 3 months
* Had hypertension (Predialysis systolic blood pressure (SBP) greater than 140 mmHg, averaged over preceding 6 dialysis treatments)
* Had a stable dry weight over preceding 6 dialysis treatments



**5.4 Study Design for background**

The main objective is to assess how impaired renal function affects the pharmacokinetics (PK) of the drug and to ascertain whether the observed changes warrant a dosage adjustment. This objective can be achieved through various methods, tailored to the drug's properties and the target patient population.

To comprehensively understand how impaired renal function influences the pharmacokinetics (PK) of a drug, it's essential to include participants with a spectrum of renal function, ranging from normal to severely impaired. The renal function classification provided in Table 1 serves as a useful tool for enrolling participants in dedicated renal impairment studies. Additionally, it can aid in formulating dosing recommendations based on the observed PK outcomes.

**Sec 6** **Applicable clinical, epidemiological, or public health background or context of the clinical trial**

**6.1 Importance of the research**

Chronic kidney disease (CKD) is rare in horses with an overall prevalence reported to be 0.12%. There is often a continuum from Acute Kidney Injury (AKI) to CKD, and patients with CKD may be predisposed to episodes of AKI. The most common clinical signs are non-specific with weight loss, polyuria/polydipsia and ventral edema. Less common clinical signs are poor appetite and performance, dull hair coat, oral ulcerations, gastro-intestinal ulceration, gingivitis, dental tartar and diarrhea.

Norepinephrine is currently recommended as the first-line vasopressor in septic shock; however, early vasopressin use has been proposed as an alternative. Hence, the effectiveness of Vasopressin is important to be established.

**6.2 Objective of the research**

To measure the effectiveness of early vasopressin in comparison on kidney failure in patients with septic shock.

**6.3 Use of the drug in specific populations**

Pregnancy Risk Summary:

There is a lack of available data on the use of vasopressin in pregnant women, making it difficult to assess the risk of major birth defects, miscarriage, or adverse outcomes for both the mother and fetus.

Clinical Considerations: Dose adjustments during pregnancy and the postpartum period: Due to increased clearance of vasopressin in the second and third trimesters, it may be necessary to adjust the dosage of vasopressin accordingly. Maternal adverse reactions: Vasopressin could lead to uterine contractions that may risk continuing pregnancy.

Lactation: There is no available data regarding the presence of vasopressin injection in human or animal milk, its effects on breast-fed infants, or its impact on milk production.

Pediatric Use: The safety and efficacy of vasopressin in pediatric patients with vasodilatory shock have not been established.

Geriatric Use: Clinical trials involving vasopressin did not involve enough subjects aged 65 and older to determine if they respond differently compared to younger subjects. However, reported clinical experience has not indicated any notable differences in responses between elderly and younger patients. Generally, caution should be exercised in selecting doses for elderly patients, typically starting at the lower end of the dosage range, due to the higher likelihood of decreased hepatic, renal, or cardiac function, as well as the presence of concurrent diseases or other medications.

**Sec 7** **Importance of the clinical trial and any relevant treatment issues or controversies**

**7.1 Adverse events**

Method of systematic assessment used was Physician assessment.

The time frame would be for 3 weeks.

**7.2 Possible side effects**

TERLIVAZ increases the risk of serious or fatal respiratory (breathing) failure. Patients with low oxygen in their blood should not start the medication. During treatment, patients should be monitored for breathing problems with a pulse oximeter, a tool that measures oxygen levels in the blood. Side effects of TERLIVAZ may prevent patients from receiving a liver transplant. TERLIVAZ can cause ischemic events (that occur when blood does not reach certain parts of the body) that may require pausing or stopping treatment; the medication may also cause fetal harm when used during pregnancy.

**7.3 Drug interactions**

|  |  |
| --- | --- |
| A[mitriptyline](https://go.drugbank.com/drugs/DB00321) | Amitriptyline may increase the fluid retaining and vasopressor activities of Vasopressin. |
| [Amitriptylinoxide](https://go.drugbank.com/drugs/DB13114) | Amitriptylinoxide may increase the fluid retaining and vasopressor activities of Vasopressin. |
| [Amoxapine](https://go.drugbank.com/drugs/DB00543) | Amoxapine may increase the fluid retaining and vasopressor activities of Vasopressin. |
| [Ardeparin](https://go.drugbank.com/drugs/DB00407) | The therapeutic efficacy of Vasopressin can be decreased when used in combination with Ardeparin. |
| [Bemiparin](https://go.drugbank.com/drugs/DB09258) | The therapeutic efficacy of Vasopressin can be decreased when used in combination with Bemiparin. |

**7.4 Over dosage**

Overdosage with vasopressin can be expected to manifest as consequences of vasoconstriction of various vascular beds (peripheral, mesenteric, and coronary) and as hyponatremia. In addition, overdosage may lead less commonly to ventricular tachyarrhythmias (including Torsade de Pointes), rhabdomyolysis, and non-specific gastrointestinal symptoms. Direct effects will resolve within minutes of withdrawal of treatment.

**Explanation:**

**Section 3:** *This section displays a summary of different factors related to drug-related information from sources like DailyMed, DrugBank like Summary, Background, Structure, Weight, Chemical Formula, Indications and usage, Associated Conditions, Associated Therapies, Mechanism of action, Metabolism, Route of elimination, Half-life, Toxicity, Dosage and administration, Contraindications, Warnings and precautions, Clinical Pharmacology- Pharmacodynamics, Pharmacokinetics, Non-clinical toxicology, Clinical Studies and Storage and handling information of the drug*

**Section 4:** *This section displays a summary of different aspects to relevant clinical research from sources like Clinicaltrials.gov and* [*FDA website*](https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-terlivaz)

*4.1 Results Overview from previous clinical trials: This displays a summary of what has happened in the previous clinical trials and what conditions the drug is associated with*

*4.2 Trial Description: This displays a brief summary of study type or the design of the trial*

*4.3 Drug trial snapshots: This shows a quick overview of related drugs to the one in the study*

*4.4 Participant Flow: This section shows progression of participants through various stages of a clinical trial, from enrollment to completion. This includes the number of participants who started, completed, and dropped out of the study, also highlighting the reasons why the trial was discontinued*

*4.5 Record History: This table shows all the versions of this study record arranged in order by submitted date*

*4.6 Study record dates: These dates track the progress of study record and summary results submissions to ClinicalTrials.gov*

*4.7 Intervention and Treatment: this section shows processes or actions that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available.*

*4.8 Outcome Measures of previous clinical trials: This section highlights the specific parameters, variables, or endpoints used to evaluate the effects of an intervention or treatment being studied*

**Section 5:**

*5.1 Summary of related research articles – This part contains information summarized from the relevant research articles*

*5.2 Main outcomes and measures of research articles- This includes the results found in various research papers pertaining to our topic.*

*5.3 Demographic profile-* *This talks about the various demographic profiles of the selected candidates for the trial.*

*5.4 Study Design for background- This part talks about how we are going to design the trial or the study of the patients. We will need understanding of the trial objectives and data about study design to design the study in a way that gives optimum results. This data can be gathered from FDA site.*

**Section 6:** This section talks about the importance or the context to why this particular clinical trial is being conducted. It will contain the major objectives and importance of the trial with giving some background on the patient population.

*6.1 Importance of the research*

*6.2 Objective of the research*

*6.3 Use of the drug in specific populations- This refers to the various complications or issues that can arise in certain populations on consuming this drug. This information can be found in portals like DailyMed which give all round information about the drug.*

**Section 7:** This sectionre-instates the importance of the clinical trial and gives information on any relevant treatment issues or controversies occurred in the past trials or any research.

*7.1 Adverse events - Refers to any unforeseen complications occurring in any past records.*

*7.2 Possible side effects*

*7.3 Drug interactions*

*7.4 Over dosage*